Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor Compstatin

Journal of Immunology

Volumn 165, Issue 5, 2000, Pages 2491-2499

  Sahu, A ^a   Soulika, A M ^a   Morikis, D ^a   Spruce, L ^a   Moore, W T ^a   Lambris, J D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT INHIBITOR;

ACETYLATION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOTRANSFORMATION; COMPLEMENT ACTIVATION; DISULFIDE BOND; ENZYME DEGRADATION; ISOMERISM; OPTICAL ROTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

EID: 0034283672     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.5.2491     Document Type: Article

References (49)

1. Therapeutic uses of recombinant complement protein inhibitors
2. Activation of the complement system in the adult respiratory distress syndrome
3. Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide
4. Complement activation by β-amyloid in Alzheimer-disease
5. Involvement of the complement system in cerebral ischemic and reperfusion injury
6. The complement system in myocardial ischaemia/reperfusion injury
7. The role of the complement system in trauma and infection
8. Terminal complement-complex in myocardial reperfusion injury
9. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement
10. Complement activation by biomaterials
11. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction
12. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin
13. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts
14. Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library
15. Solution structure of Compstatin, a potent complement inhibitor
16. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation
17. Inhibition of heparin/ptotamin complex-induced complement activation by Compstatin in baboons
18. Large scale isolation of functionally active components of the human complement system
19. A fluorimetric assay for native C3: The hemolytically active form of the third component of human complement
20. Identification of the C3b receptor-binding domain in third component of complement
21. A novel lysine-protecting procedure for continuous-flow solid-phase synthesis of branched peptides
22. Laser desorption mass spectrometry
23. Formation of disulfide bond in an octreotide-like peptide: A multicenter study
24. Kinetics and thermodynamics of virus binding to receptor: Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance
25. Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor
26. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3
27. Nucleophilic modification of human complement protein C3: Correlation of conformational changes with acquisition of C3b-like functional properties
28. Formation of the initial C3 convertase of the alternative pathway: Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3
29. Recent development in retro peptides and protein in ongoing topochemical expiration
30. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
31. Turns in peptides and proteins
32. Complement inhibitors targeting C3, C4, and C5
33. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
34. Structure and function of decay accelerating factor CD55
35. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro
36. Anti-C5 single chain antibody therapy blocks complement and leukocyte activation and reduces myocardial tissue damage in CPB patients
37. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikren and trypsin
38. Localization of Compstatin binding site on C3
39. Receptor-induced conformation change of the immunosuppressant cyclosporine-A
40. Interaction of cyclosporin A with an Fab fragment or cyclophilin: Affinity measurements and time-dependent changes in binding
41. Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis
42. The chemistry and biology of C3, C4, and C5
43. Antigenic mimicry of natural L-peptides with retro-inverso peptidomimetics
44. The retro-inverso form of a homebox-derived short peptide is rapidly internalized by cultured neurons: A new basis for an efficient intracellular delivery system
45. Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors
46. Conformation of a system of three linked peptide units
47. Synthetic peptide inhibitors of complement serine proteases, 1I. Effects on hemolytic activity and production of C3a and C4a
48. Synthetic peptide inhibitors of complement serine proteases. I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D
49. Complement-inhibiting peptides identified by proximity to indels in the C3/4/5 protein family